Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Shkreli and Schiller To Testify At Congressional Hearing On Drug Pricing

XTALKS NEWS

Drug Pricing

The house committee has subpoenaed Shkreli, and expects both Turing and Valeant to provide documentation regarding their drug pricing policies.

Share this!

January 22, 2016 | by Sarah Massey, M.Sc.

Former Turing Pharma CEO Martin Shkreli, and Valeant Pharmaceutical’s interim CEO Howard Schiller are expected to participate in a Congressional hearing on pharmaceutical pricing set for January 26. The house committee has subpoenaed Shkreli, and expects both Turing and Valeant to provide documentation regarding their drug pricing policies.

Both companies faced public backlash last year – Valeant increased the price of the heart drugs Nitropess and Isuprel, and Turing did the same with the antiparasitic drug Daraprim. Schiller is currently acting as interim CEO of Valeant, while the company’s chief executive, J. Michael Pearson is on medical leave with pneumonia.

While it’s uncertain whether Shkreli will comply with the subpoena, Valeant’s Schiller is reportedly eager to testify in order to begin the process of rebuilding the company’s public image. During last week’s J.P. Morgan Healthcare Conference, the interim CEO has vowed to change the company’s pricing policies in order to make their pharmaceuticals more affordable for patients.



“We will be relentlessly focused on providing easy and affordable access for physicians and patients,” said Schiller. He also disclosed that the company would place more emphasis on R&D in 2016.

House Oversight and Government Reform Committee ranking member Representative Elijah Cummins has been after Turing and Valeant for more than a year, and is reportedly happy that both political parties are in favour of a drug pricing investigation. According to Cummins, Americans are “fed up with watching major drug companies rake in record profits while they continue to struggle to afford their medicines.”

Martin Shkreli made waves last year when his company, Turing Pharmaceuticals, acquired the toxoplasmosis drug Daraprim and subsequently hiked up the price by over 5,000 percent. He has since stepped down as CEO of the company amid charges of securities fraud at his former hedge fund, MSMB Capital Management.

WATCH & PARTICIPATE IN THESE WEBINARS 


 

The Three Sins of GMP Executives

Cancer Immunotherapy: Advancing and Accelerating Discovery Programs


Keywords: Drug Pricing, Martin Shkreli, Valeant Pharmaceuticals


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Sanofi Pasteur Provides Funding To The Human Vaccines Project

January 21, 2016 - Sanofi’s vaccines unit, Sanofi Pasteur, has agreed to partially fund the Human Vaccines Project – a non- profit, global consortium of researchers and private partners working towards a better understanding of the human immune system.


Dissolvable Brain Sensor Developed To Monitor Patients With Traumatic Brain Injury

January 20, 2016 - A group of neurosurgeons and engineers from the Washington University School of Medicine, in collaboration with researchers from the University of Illinois at Urbana- Champaign, have developed a bioresorbable brain sensor that eliminates the need for additional surgery to remove the device.


FDA Highlights Cybersecurity Measures For Medical Device Manufacturers

January 20, 2016 - Earlier this week, the US Food and Drug Administration (FDA) released a draft guidance document detailing measures to be taken by medical device manufacturers, in order to ensure the postmarket cybersecurity of their devices.

LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.